Hvilken er prisen på Vaxil Bio Ltd. (VXL)

Prisen på Vaxil Bio Ltd. (VXL) er $0.1174299

Hva er markedsverdien på Vaxil Bio Ltd. (VXL)

Markedsverdien på Vaxil Bio Ltd. (VXL) er $467.84K

Vaxil Bio Ltd. (VXL) Fortjeneste per Aksje

Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.

År	EPS	Endre
Ikke nok data for de angitte datoene.

År

EPS

Endre

Ikke nok data for de angitte datoene.

Selskap	EPS	EPS-forskjell	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-	BE

Selskap

EPS

EPS-forskjell

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

$17.32

Argenx SE

ARGX.US

$27.74

Lonza Group AG

LONN.SW

Samsung Biologics Co.,Ltd.

207940.KS

UCB S.A.

UCB.BR

$13.70

Vaxil Bio Ltd.

VXL

Kategori